Rytary Shortage: What Providers and Prescribers Need to Know in 2026

For neurologists, movement disorder specialists, and primary care physicians managing Parkinson's disease patients, the carbidopa-levodopa supply landscape in 2026 presents a multifaceted access challenge. While Rytary (carbidopa and levodopa extended-release capsules, Amneal Pharmaceuticals) is not in a formal FDA-listed shortage, the broader carbidopa-levodopa ecosystem — particularly generic extended-release formulations — is in active, ongoing shortage that affects patient care decisions daily.

This article provides a concise, clinically oriented overview of the current supply landscape, its prescribing implications, and actionable strategies to support patient access to Rytary and carbidopa-levodopa formulations in 2026.

Current Supply Status: What Is and Isn't in Shortage

Understanding the tiered availability picture is essential for guiding prescribing and patient counseling:

Generic carbidopa-levodopa IR tablets: Generally available from multiple manufacturers (Teva, Amneal, Sun, others). Localized spot shortages persist but overall supply is relatively stable.

Generic carbidopa-levodopa ER tablets (25/100 mg, 50/200 mg): ASHP-listed shortage as of 2026. Accord Healthcare discontinued the 25/100 mg strength entirely. Only the 50/200 mg strength remains available from a limited number of manufacturers.

Rytary (brand ER capsules): Available but not routinely stocked at most retail pharmacies. Requires specialty pharmacy channel or advance ordering in most cases. Not in FDA/ASHP shortage.

Crexont (carbidopa-levodopa ER capsules, approved 2024): Brand only. Available but similarly requires specialty pharmacy access. Offers a ~1:1 conversion from Rytary by levodopa content.

Duopa (carbidopa-levodopa enteral suspension): Specialty product, available through designated channels. AbbVie offers patient support programs.

Prescribing Implications: Converting Between Formulations

A critical point for all clinicians: carbidopa-levodopa formulations are NOT interchangeable on a 1:1 basis. This applies to IR vs. ER vs. Rytary vs. Crexont. Conversion errors are a significant patient safety concern.

IR to Rytary: Use the manufacturer's conversion table (Table 1 in the Rytary prescribing information). Starting dose is based on the patient's current total daily levodopa dose.

Rytary to Crexont: Approximately 1:1 based on the levodopa component. Still requires monitoring and titration post-switch.

Adding entacapone (Stalevo or separate): Typically requires a 10–30% reduction in levodopa dose when initiating COMT inhibition. Monitor for dyskinesia.

Instruct patients never to split, crush, or chew Rytary capsules. Contents can be sprinkled on applesauce for patients with dysphagia, but this is the only approved modification. Doses must be tapered to discontinue — abrupt withdrawal risks neuroleptic malignant syndrome (NMS).

Formulary and Prior Authorization Considerations

Rytary typically requires prior authorization on most commercial insurance plans and Medicare Part D. The PA criteria commonly require documented failure or inadequate response to immediate-release carbidopa-levodopa. Key formulary considerations:

Document motor fluctuations ('wearing off,' dyskinesia) to support PA justification for Rytary.

Amneal's savings card (PhilRx) reduces copays for commercially insured patients to $0–$20/month. Provide this to patients at the time of prescribing.

Medicare Part D coverage varies significantly by plan. Some plans classify Rytary as a non-preferred brand (Tier 3–4) with step therapy requirements.

The 'eight tablet daily limit' is a known barrier — some plans invoke this language from original Sinemet labeling. Submit a medical necessity exception for patients who require higher doses.

Cost Landscape for Clinical Counseling

Understanding costs helps providers counsel patients proactively and reduce abandonment at the pharmacy:

Generic IR tablets: $8–$17 cash; $0–$15 with insurance (Tier 1 preferred generic)

Generic ER tablets: $30–$80 cash; $0–$15 with insurance — when available

Rytary: $800–$1,500/month retail cash; $322–$480 for 100 capsules with coupons; $0–$20/month for commercially insured with Amneal savings card

Actionable Strategies for Providers

To minimize disruption for your patients, consider these approaches:

Direct Rytary patients to specialty pharmacies your practice has established relationships with, rather than standard retail chains.

Always provide the Amneal/PhilRx savings card information at the time of prescribing to commercially insured patients.

Use medfinder for Providers to check real-time pharmacy availability in your patient's area before writing a prescription for a specific Rytary strength combination.

Document all motor fluctuation symptoms thoroughly in the medical record to support PA approvals and appeals.

Counsel all Rytary patients to start refill searches 7–10 days before supply runs out and to never stop abruptly.

Consider Crexont as an alternative for patients experiencing repeated Rytary access issues — its twice-daily dosing may also improve adherence.